OculoTherapy

OculoTherapy is an early-stage start-up with a novel IOP-lowering eye drop for use in patients with primary open angle glaucoma or ocular hypertension. We demonstrated that topical administration of our eye drops engineered to include bioadhesive and extended-release properties reduced IOP in mice and rabbits in a dose-dependent manner with efficacy and duration that were equal to or greater than those reported for currently available medications, while concomitantly offering a much-needed new mechanism of action. We have recently filed our pre-IND meeting request with the FDA and are seeking guidance on our chemistry, manufacturing and controls, nonclinical and clinical development plans. Because our API is a repurposed FDA approved drug, we plan to use the 505(b)(2) regulatory pathway. We have reached this stage of development with non-dilutive funding and hope to seek strategic partnership and outside investment to carry us through Phase 2 clinical trials.